Literature DB >> 29383494

Two-step progression of varenicline-induced autoimmune hepatitis.

Mitsuru Sakakibara1, Kazuyoshi Ohkawa2, Takatoshi Nawa2, Yutaro Abe2, Akira Kusakabe2, Toshihiro Imai2, Kazuhiro Katayama2.   

Abstract

We describe a rare case of drug-induced hepatitis due to the smoking cessation agent varenicline in a 46-year-old Asian woman. The liver injury progressed in two steps. First, the liver injury started in the absence of viral/autoimmune responses, and withdrawal of varenicline lowered the increase in the levels of liver enzymes immediately. Such findings suggested varenicline-induced liver injury. Second, hepatitis recurred in association with conversion of antinuclear antibody from negative to positive about 8 weeks after the initial episode. Histology upon recurrence of liver injury revealed interface hepatitis with lymphocytic and lymphoplasmacytic portal inflammatory infiltrates extending into lobules. Such findings suggested autoimmune hepatitis. Corticosteroid treatment was effective for recurrent hepatitis. The clinical course suggests that varenicline caused drug-induced liver injury and subsequent autoimmune hepatitis. Some autoimmune changes were probably involved in the mechanism of varenicline-induced liver injury.

Entities:  

Keywords:  AIH; Autoimmune hepatitis; DILI; Drug-induced liver injury; Varenicline

Mesh:

Substances:

Year:  2018        PMID: 29383494     DOI: 10.1007/s12328-018-0824-x

Source DB:  PubMed          Journal:  Clin J Gastroenterol        ISSN: 1865-7265


  14 in total

1.  Tamoxifen-induced non-alcoholic steatohepatitis in patients with breast cancer: determination of a suitable biopsy site for diagnosis.

Authors:  Yoriko Murata; Yasuhiro Ogawa; Toshiji Saibara; Akihito Nishioka; Naoko Takeuchi; Shinji Kariya; Saburo Onishi; Shoji Yoshida
Journal:  Oncol Rep       Date:  2003 Jan-Feb       Impact factor: 3.906

2.  Tamoxifen-induced hepatotoxicity.

Authors:  N Ahbeddou; R Belbaraka; M Fetohi; H Errihani
Journal:  Indian J Cancer       Date:  2011 Jul-Sep       Impact factor: 1.224

3.  Drug induced liver injury and its relationship to autoimmune hepatitis.

Authors:  Christina Weiler-Normann; Christoph Schramm
Journal:  J Hepatol       Date:  2011-03-09       Impact factor: 25.083

4.  Varenicline-induced acute liver injury with jaundice.

Authors:  Helga Mogensen; Einar S Björnsson
Journal:  Hepatology       Date:  2015-04-27       Impact factor: 17.425

5.  Role of Th1/Th2 cells and related cytokines in autoimmune hepatitis.

Authors:  Farinaz Behfarjam; Mohammad Hossein Sanati; Siavash Nasseri Moghaddam; Mitra Ataei; Sepideh Nikfam; Zohreh Jadali
Journal:  Turk J Gastroenterol       Date:  2017-01-25       Impact factor: 1.852

6.  Autoimmune-like drug-induced liver injury: a review and update for the clinician.

Authors:  Jonathan G Stine; Patrick G Northup
Journal:  Expert Opin Drug Metab Toxicol       Date:  2016-07-21       Impact factor: 4.481

7.  Standardization of nomenclature and causality assessment in drug-induced liver injury: summary of a clinical research workshop.

Authors:  Robert J Fontana; Leonard B Seeff; Raúl J Andrade; Einar Björnsson; Christopher P Day; Jose Serrano; Jay H Hoofnagle
Journal:  Hepatology       Date:  2010-08       Impact factor: 17.425

8.  Acute hepatic injury associated with varenicline in a patient with underlying liver disease.

Authors:  Andrew J Franck; Lisa R Sliter
Journal:  Ann Pharmacother       Date:  2009-07-28       Impact factor: 3.154

9.  Diagnostic criteria for autoimmune hepatitis.

Authors:  Ansgar W Lohse; Elke Hennes
Journal:  Hepatol Res       Date:  2007-10       Impact factor: 4.288

10.  Drug-induced liver injury due to varenicline: a case report.

Authors:  David Sprague; Kiran Bambha
Journal:  BMC Gastroenterol       Date:  2012-06-08       Impact factor: 3.067

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.